Developmental Research Program

认识到发展研究资金是孢子不可分割的一部分，我们承诺大约 每年为这些努力提供15万美元。这是前列腺癌孢子预算的很大一部分， 反映了对前列腺癌创新转化研究发展的持续承诺。 发展研究计划(DRP)的重点是为研究人员提供产生 提交R01拨款申请或同等建议书的初步数据。调查人员来自 在前列腺癌领域之外，鼓励通过校园范围的公告以及 通过与孢子调查人员的个人互动。我们制定了一个循序渐进的方案征集方案， 使用NIH类型的PHS 398格式的试点项目的审查过程已简化，以实现快速 研究建议的周转，并认识到这些项目可能几乎没有初步数据。 自1995年以来，我们在DRP上投资了390万美元，通过77个试点项目总共资助了89名调查人员， 63个种子助学金和35个暑期学生项目。这些奖项在随后的比赛中获得了超过4000万美元的收入 孢子和非孢子经同行评审的资金和超过136份已发表的手稿。在这股海流中 在赠款周期中，我们资助了9个试点项目(每个项目5万美元)，这些项目在随后的同行审查中获得了超过970万美元的资金 赠款资助和22种出版物。伊丽莎白·希思博士(卡尔马诺斯癌症研究所，KCI)和埃文·凯勒博士(U- M)将担任DRP的联席董事。希思博士是韦恩州立大学肿瘤学和医学教授 他是KCI大学前列腺癌研究部主任。她是国防部资助的首席调查员 前列腺癌临床试验协会，其中KCI是总体患者和少数人收益的领先网站 前列腺癌的临床试验中。她曾指导过无数的本科生、医学生、癌症患者 生物学研究生和初级教职员工，并将担任临床专家。凯勒博士是一位教授 UM罗杰尔癌症中心泌尿外科肿瘤学项目联席主任， 指导一项由美国国立卫生研究院资助的前列腺癌骨转移项目，同时也是Single 细胞分析核心，并将担任基础科学专家。在这项提案中，DRP将得到共同支持 由密歇根州立大学和KCI。密歇根大学将捐赠50,000美元外加资金，用于支付密歇根大学联席主任的工作费用。KCI将 捐助50,000美元，用于支持一名KCI调查员的DRP或CEP奖项，以及 KCI联席主任。我们要求NCI提供剩余的50,000美元。

Recognizing that developmental research funds are an integral part of the SPORE, we commit approximately $150,000 per year to these endeavors. This represents a significant portion of the Prostate SPORE budget and reflects the continued commitment to the development of innovative translational research in prostate cancer. The focus of the Developmental Research Program (DRP) is to provide investigators the resources to generate preliminary data for the submission of an R01 grant application or an equivalent proposal. Investigators from outside the field of prostate cancer are encouraged to apply through campus-wide announcements as well as through personal interactions with the SPORE investigators. We developed a stepwise proposal solicitation and review process for pilot projects utilizing an NIH-type PHS 398 format that has been streamlined for rapid turnaround of research proposals and which recognizes that these projects may have little preliminary data. Since 1995, we have invested $3.9 million in our DRP, funding a total of 89 investigators though 77 pilot projects, 63 seed grants and 35 summer student projects. These awards have led to over $40 million in subsequent SPORE and non-SPORE peer-reviewed funding and over 136 published manuscripts. During this current grant cycle, we funded 9 pilot projects ($50K each) that led to over $9.7 million in subsequent peer-reviewed grant funding and 22 publications. Drs. Elisabeth Heath (Karmanos Cancer Institute, KCI) and Evan Keller (U- M) will serve as Co-Directors for the DRP. Dr. Heath is a Professor of Oncology and Medicine, at Wayne State University and Director of Prostate Cancer Research KCI. She is the Principal Investigator of the DOD-funded Prostate Cancer Clinical Trials Consortium where KCI is the leading site for overall patient and minority accrual in prostate cancer clinical trials. She has mentored numerous undergraduate students, medical students, cancer biology graduate students, and junior faculty members and will serve as a clinical expert. Dr. Keller is a Professor of Urology and Pathology, at UM, Co-Director of the Urologic Oncology program of the UM Rogel Cancer Center, directs an NIH-funded Program Project on Prostate Cancer Bone Metastasis and is Co-Director of the Single Cell Analysis Core and will serve as basic science expert. In this proposal, the DRP will be jointly supported by U-M and KCI. U-M will contribute $50,000 plus funds to cover effort for the U-M Co-Director. KCI will contribute $50,000 to support either a DRP or CEP award for a KCI investigator as well as funds to cover the KCI Co-Director. We are requesting the remaining $50,000 from NCI.